Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Graefe's Archive for Clinical and Experimental Ophthalmology
Literature
1.
2.
Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMed
3.
Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS (2006) Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 124:193–198CrossRefPubMedPubMedCentral
4.
Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data formacular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRef
5.
Kuppermann BD, Haller JA, Bandello F (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:1743–1749CrossRefPubMed
6.
Coscas G, Augustin A, Bandello F et al (2014) Retreatment with ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24:1–9CrossRefPubMed
7.
Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMed
8.
Călugăru D, Călugăru M (2015) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 Galileo study. Am J Ophthalmol 159:607–608CrossRefPubMed
9.
Călugăru D, Călugăru M (2016) Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for Retinal Vein Occlusion (ORVO) Study. Am J Ophthalmol 161:215–216CrossRefPubMed
Metadata
Title
Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial
Authors
Dan Călugăru
Mihai Călugăru
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3559-8

Other articles of this Issue 2/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 2/2017 Go to the issue

Retinal Disorders

Treatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab

Pediatrics

Apgar score and reduced vision in children aged 3 to 6 years

Retinal Disorders

Long-term outcomes of sutureless 25-G+ pars-plana vitrectomy for the management of diabetic tractional retinal detachment

Cataract

The clinical depth of field achievable with trifocal and monofocal intraocular lenses: theoretical considerations and proof of concept clinical results

Letter to the Editor

The effects of vitreous on proliferative diabetic retinopathy and the response to pan retinal photocoagulation

Retinal Disorders

Long-term results and recurrence rates after spironolactone treatment in non-resolving central serous chorio-retinopathy (CSCR)